Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 91 entries
Sorted by: Best Match Show Resources per page
AID/APOBEC deaminases and cancer.

Oncoscience

Rebhandl S, Huemer M, Greil R, Geisberger R.
PMID: 26097867
Oncoscience. 2015 Apr 28;2(4):320-33. doi: 10.18632/oncoscience.155. eCollection 2015.

Mutations are the basis for evolution and the development of genetic diseases. Especially in cancer, somatic mutations in oncogenes and tumor suppressor genes alongside the occurrence of passenger mutations have been observed by recent deep-sequencing approaches. While mutations have...

Cite
Rebhandl S, Huemer M, Greil R, et al. AID/APOBEC deaminases and cancer. Oncoscience. 2015;2(4):320-33doi: 10.18632/oncoscience.155.
Rebhandl, S., Huemer, M., Greil, R., & Geisberger, R. (2015). AID/APOBEC deaminases and cancer. Oncoscience, 2(4), 320-33. https://doi.org/10.18632/oncoscience.155
Rebhandl, Stefan, et al. "AID/APOBEC deaminases and cancer." Oncoscience vol. 2,4 (2015): 320-33. doi: https://doi.org/10.18632/oncoscience.155
Rebhandl S, Huemer M, Greil R, Geisberger R. AID/APOBEC deaminases and cancer. Oncoscience. 2015 Apr 28;2(4):320-33. doi: 10.18632/oncoscience.155. eCollection 2015. PMID: 26097867; PMCID: PMC4468319.
Copy Download .nbib Format: NLM
Lenalidomide overcomes the immunosuppression of regulatory CD8.

Oncotarget

Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M.
PMID: 29228683
Oncotarget. 2017 Oct 05;8(58):98200-98214. doi: 10.18632/oncotarget.21516. eCollection 2017 Nov 17.

Although lenalidomide and pomalidomide are well-established treatment options in patients with multiple myeloma, their immune-modulating effects are not fully understood. While CD8

Cite
Neuber B, Dai J, Waraich WA, et al. Lenalidomide overcomes the immunosuppression of regulatory CD8. Oncotarget. 2017;8(58):98200-98214doi: 10.18632/oncotarget.21516.
Neuber, B., Dai, J., Waraich, W. A., Awwad, M. H. S., Engelhardt, M., Schmitt, M., Medenhoff, S., Witzens-Harig, M., Ho, A. D., Goldschmidt, H., & Hundemer, M. (2017). Lenalidomide overcomes the immunosuppression of regulatory CD8. Oncotarget, 8(58), 98200-98214. https://doi.org/10.18632/oncotarget.21516
Neuber, Brigitte, et al. "Lenalidomide overcomes the immunosuppression of regulatory CD8." Oncotarget vol. 8,58 (2017): 98200-98214. doi: https://doi.org/10.18632/oncotarget.21516
Neuber B, Dai J, Waraich WA, Awwad MHS, Engelhardt M, Schmitt M, Medenhoff S, Witzens-Harig M, Ho AD, Goldschmidt H, Hundemer M. Lenalidomide overcomes the immunosuppression of regulatory CD8. Oncotarget. 2017 Oct 05;8(58):98200-98214. doi: 10.18632/oncotarget.21516. eCollection 2017 Nov 17. PMID: 29228683; PMCID: PMC5716723.
Copy Download .nbib Format: NLM
The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Oncoimmunology

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.
PMID: 30288348
Oncoimmunology. 2018 Aug 01;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

No abstract available.

Cite
Awwad MHS, Kriegsmann K, Plaumann J, et al. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology. 2018;7(10):e1486356doi: 10.1080/2162402X.2018.1486356.
Awwad, M. H. S., Kriegsmann, K., Plaumann, J., Benn, M., Hillengass, J., Raab, M. S., Bertsch, U., Munder, M., Weisel, K., Salwender, H. J., Hänel, M., Fenk, R., Dürig, J., Müller-Tidow, C., Goldschmidt, H., & Hundemer, M. (2018). The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology, 7(10), e1486356. https://doi.org/10.1080/2162402X.2018.1486356
Awwad, Mohamed H S, et al. "The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma." Oncoimmunology vol. 7,10 (2018): e1486356. doi: https://doi.org/10.1080/2162402X.2018.1486356
Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M. The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma. Oncoimmunology. 2018 Aug 01;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018. PMID: 30288348; PMCID: PMC6169592.
Copy Download .nbib Format: NLM
Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Oncotarget

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.
PMID: 29156688
Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.

BACKGROUND: Raising T-cell response against antigens either expressed on normal and malignant plasma cells (e.g. HM1.24) or aberrantly on myeloma cells only (e.g. cancer testis antigens, CTA) by vaccination is a potential treatment approach for multiple myeloma.RESULTS: Expression by...

Cite
Schmitt M, Hückelhoven AG, Hundemer M, et al. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016;8(49):84847-84862doi: 10.18632/oncotarget.11215.
Schmitt, M., Hückelhoven, A. G., Hundemer, M., Schmitt, A., Lipp, S., Emde, M., Salwender, H., Hänel, M., Weisel, K., Bertsch, U., Dürig, J., Ho, A. D., Blau, I. W., Goldschmidt, H., Seckinger, A., & Hose, D. (2017). Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget, 8(49), 84847-84862. https://doi.org/10.18632/oncotarget.11215
Schmitt, Michael, et al. "Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial." Oncotarget vol. 8,49 (2017): 84847-84862. doi: https://doi.org/10.18632/oncotarget.11215
Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D. Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial. Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17. PMID: 29156688; PMCID: PMC5689578.
Copy Download .nbib Format: NLM
CCR5 status and metastatic progression in colorectal cancer.

Oncoimmunology

Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N.
PMID: 31428524
Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019.

Multiple reports have highlighted the importance of the local immunological cellular composition (

Cite
Suarez-Carmona M, Chaorentong P, Kather JN, et al. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019;8(9):e1626193doi: 10.1080/2162402X.2019.1626193.
Suarez-Carmona, M., Chaorentong, P., Kather, J. N., Rothenheber, R., Ahmed, A., Berthel, A., Heinzelmann, A., Moraleda, R., Valous, N. A., Kosaloglu, Z., Eurich, R., Wolf, J., Grauling-Halama, S., Hundemer, M., Lasitschka, F., Klupp, F., Kahlert, C., Ulrich, A., Schneider, M., Falk, C., Jäger, D., Zoernig, I., & Halama, N. (2019). CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology, 8(9), e1626193. https://doi.org/10.1080/2162402X.2019.1626193
Suarez-Carmona, Meggy, et al. "CCR5 status and metastatic progression in colorectal cancer." Oncoimmunology vol. 8,9 (2019): e1626193. doi: https://doi.org/10.1080/2162402X.2019.1626193
Suarez-Carmona M, Chaorentong P, Kather JN, Rothenheber R, Ahmed A, Berthel A, Heinzelmann A, Moraleda R, Valous NA, Kosaloglu Z, Eurich R, Wolf J, Grauling-Halama S, Hundemer M, Lasitschka F, Klupp F, Kahlert C, Ulrich A, Schneider M, Falk C, Jäger D, Zoernig I, Halama N. CCR5 status and metastatic progression in colorectal cancer. Oncoimmunology. 2019 Jul 13;8(9):e1626193. doi: 10.1080/2162402X.2019.1626193. eCollection 2019. PMID: 31428524; PMCID: PMC6685512.
Copy Download .nbib Format: NLM
Draft Genome Sequence of .

Microbiology resource announcements

Hausmann B, Pjevac P, Huemer M, Herbold CW, Pester M, Loy A.
PMID: 31320430
Microbiol Resour Announc. 2019 Jul 18;8(29). doi: 10.1128/MRA.00428-19.

No abstract available.

Cite
Hausmann B, Pjevac P, Huemer M, et al. Draft Genome Sequence of . Microbiol Resour Announc. 2019;8(29)doi: 10.1128/MRA.00428-19.
Hausmann, B., Pjevac, P., Huemer, M., Herbold, C. W., Pester, M., & Loy, A. (2019). Draft Genome Sequence of . Microbiology resource announcements, 8(29), . https://doi.org/10.1128/MRA.00428-19
Hausmann, Bela, et al. "Draft Genome Sequence of ." Microbiology resource announcements vol. 8,29 (2019). doi: https://doi.org/10.1128/MRA.00428-19
Hausmann B, Pjevac P, Huemer M, Herbold CW, Pester M, Loy A. Draft Genome Sequence of . Microbiol Resour Announc. 2019 Jul 18;8(29). doi: 10.1128/MRA.00428-19. PMID: 31320430; PMCID: PMC6639609.
Copy Download .nbib Format: NLM
CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance.

Frontiers in immunology

Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D.
PMID: 30079070
Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018.

Monoclonal antibodies against the cell surface antigen CD38, e.g., isatuximab, daratumumab, or Mor202, have entered the therapeutic armamentarium in multiple myeloma due to single agent overall response rates of 29 vs. 36 vs. 31%, effectivity in combination regimen, e.g.,...

Cite
Seckinger A, Hillengass J, Emde M, et al. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Front Immunol. 2018;9:1676doi: 10.3389/fimmu.2018.01676.
Seckinger, A., Hillengass, J., Emde, M., Beck, S., Kimmich, C., Dittrich, T., Hundemer, M., Jauch, A., Hegenbart, U., Raab, M. S., Ho, A. D., Schönland, S., & Hose, D. (2018). CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Frontiers in immunology, 91676. https://doi.org/10.3389/fimmu.2018.01676
Seckinger, Anja, et al. "CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance." Frontiers in immunology vol. 9 (2018): 1676. doi: https://doi.org/10.3389/fimmu.2018.01676
Seckinger A, Hillengass J, Emde M, Beck S, Kimmich C, Dittrich T, Hundemer M, Jauch A, Hegenbart U, Raab MS, Ho AD, Schönland S, Hose D. CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma-Association With Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance. Front Immunol. 2018 Jul 20;9:1676. doi: 10.3389/fimmu.2018.01676. eCollection 2018. PMID: 30079070; PMCID: PMC6062598.
Copy Download .nbib Format: NLM
Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set.

Journal of inherited metabolic disease

Bösch F, Landolt MA, Baumgartner MR, Zeltner N, Kölker S, Gleich F, Burlina A, Cazzorla C, Packman W, V D Schwartz I, Vieira Neto E, Ribeiro MG, Martinelli D, Olivieri G, Huemer M.
PMID: 32785952
J Inherit Metab Dis. 2021 Jan;44(1):215-225. doi: 10.1002/jimd.12301. Epub 2020 Sep 22.

Acute intoxication-type inborn errors of metabolism (IT-IEM) such as urea cycle disorders and non-acute IT-IEM such as phenylketonuria have a major impact on paediatric patients' life. Patients have to adhere to a strict diet but may face neurocognitive impairment...

Cite
Bösch F, Landolt MA, Baumgartner MR, et al. Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set. J Inherit Metab Dis. 2020;44(1):215-225doi: 10.1002/jimd.12301.
Bösch, F., Landolt, M. A., Baumgartner, M. R., Zeltner, N., Kölker, S., Gleich, F., Burlina, A., Cazzorla, C., Packman, W., V D Schwartz, I., Vieira Neto, E., Ribeiro, M. G., Martinelli, D., Olivieri, G., & Huemer, M. (2021). Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set. Journal of inherited metabolic disease, 44(1), 215-225. https://doi.org/10.1002/jimd.12301
Bösch, Florin, et al. "Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set." Journal of inherited metabolic disease vol. 44,1 (2021): 215-225. doi: https://doi.org/10.1002/jimd.12301
Bösch F, Landolt MA, Baumgartner MR, Zeltner N, Kölker S, Gleich F, Burlina A, Cazzorla C, Packman W, V D Schwartz I, Vieira Neto E, Ribeiro MG, Martinelli D, Olivieri G, Huemer M. Health-related quality of life in paediatric patients with intoxication-type inborn errors of metabolism: Analysis of an international data set. J Inherit Metab Dis. 2021 Jan;44(1):215-225. doi: 10.1002/jimd.12301. Epub 2020 Sep 22. PMID: 32785952.
Copy Download .nbib Format: NLM
Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19.

PLoS pathogens

Mairpady Shambat S, Gómez-Mejia A, Schweizer TA, Huemer M, Chang CC, Acevedo C, Bergada-Pijuan J, Vulin C, Hofmaenner DA, Scheier TC, Hertegonne S, Parietti E, Miroshnikova N, Wendel Garcia PD, Hilty MP, Buehler PK, Schuepbach RA, Brugger SD, Zinkernagel AS.
PMID: 35007290
PLoS Pathog. 2022 Jan 10;18(1):e1010176. doi: 10.1371/journal.ppat.1010176. Epub 2022 Jan 10.

COVID-19 displays diverse disease severities and symptoms including acute systemic inflammation and hypercytokinemia, with subsequent dysregulation of immune cells. Bacterial superinfections in COVID-19 can further complicate the disease course and are associated with increased mortality. However, there is limited...

Cite
Mairpady Shambat S, Gómez-Mejia A, Schweizer TA, et al. Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. PLoS Pathog. 2022;18(1):e1010176doi: 10.1371/journal.ppat.1010176.
Mairpady Shambat, S., Gómez-Mejia, A., Schweizer, T. A., Huemer, M., Chang, C. C., Acevedo, C., Bergada-Pijuan, J., Vulin, C., Hofmaenner, D. A., Scheier, T. C., Hertegonne, S., Parietti, E., Miroshnikova, N., Wendel Garcia, P. D., Hilty, M. P., Buehler, P. K., Schuepbach, R. A., Brugger, S. D., & Zinkernagel, A. S. (2022). Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. PLoS pathogens, 18(1), e1010176. https://doi.org/10.1371/journal.ppat.1010176
Mairpady Shambat, Srikanth, et al. "Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19." PLoS pathogens vol. 18,1 (2022): e1010176. doi: https://doi.org/10.1371/journal.ppat.1010176
Mairpady Shambat S, Gómez-Mejia A, Schweizer TA, Huemer M, Chang CC, Acevedo C, Bergada-Pijuan J, Vulin C, Hofmaenner DA, Scheier TC, Hertegonne S, Parietti E, Miroshnikova N, Wendel Garcia PD, Hilty MP, Buehler PK, Schuepbach RA, Brugger SD, Zinkernagel AS. Hyperinflammatory environment drives dysfunctional myeloid cell effector response to bacterial challenge in COVID-19. PLoS Pathog. 2022 Jan 10;18(1):e1010176. doi: 10.1371/journal.ppat.1010176. Epub 2022 Jan 10. PMID: 35007290.
Copy Download .nbib Format: NLM
Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism.

American journal of hypertension

Parksook WW, Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A.
PMID: 34883509
Am J Hypertens. 2021 Dec 09; doi: 10.1093/ajh/hpab189. Epub 2021 Dec 09.

BACKGROUND: Normal-appearing adrenal glands on cross-sectional imaging may still be the source of aldosterone production in primary aldosteronism (PA).METHODS: We evaluated the prevalence of aldosterone production among morphologically normal-appearing adrenal glands and the impact of this phenomenon on interpretations...

Cite
Parksook WW, Yozamp N, Hundemer GL, et al. Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism. Am J Hypertens. 2021;doi: 10.1093/ajh/hpab189.
Parksook, W. W., Yozamp, N., Hundemer, G. L., Moussa, M., Underhill, J., Fudim, T., Sacks, B., & Vaidya, A. (2021). Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism. American journal of hypertension, . https://doi.org/10.1093/ajh/hpab189
Parksook, Wasita W, et al. "Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism." American journal of hypertension vol. (2021). doi: https://doi.org/10.1093/ajh/hpab189
Parksook WW, Yozamp N, Hundemer GL, Moussa M, Underhill J, Fudim T, Sacks B, Vaidya A. Morphologically Normal-Appearing Adrenal Glands as a Prevalent Source of Aldosterone Production in Primary Aldosteronism. Am J Hypertens. 2021 Dec 09; doi: 10.1093/ajh/hpab189. Epub 2021 Dec 09. PMID: 34883509.
Copy Download .nbib Format: NLM
Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision.

Journal of inherited metabolic disease

Forny P, Hörster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, Dixon M, Grünert SC, Grunewald S, Haliloglu G, Hochuli M, Honzik T, Karall D, Martinelli D, Molema F, Sass JO, Scholl-Bürgi S, Tal G, Williams M, Huemer M, Baumgartner MR.
PMID: 33595124
J Inherit Metab Dis. 2021 May;44(3):566-592. doi: 10.1002/jimd.12370. Epub 2021 Mar 09.

Isolated methylmalonic acidaemia (MMA) and propionic acidaemia (PA) are rare inherited metabolic diseases. Six years ago, a detailed evaluation of the available evidence on diagnosis and management of these disorders has been published for the first time. The article...

Cite
Forny P, Hörster F, Ballhausen D, et al. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J Inherit Metab Dis. 2021;44(3):566-592doi: 10.1002/jimd.12370.
Forny, P., Hörster, F., Ballhausen, D., Chakrapani, A., Chapman, K. A., Dionisi-Vici, C., Dixon, M., Grünert, S. C., Grunewald, S., Haliloglu, G., Hochuli, M., Honzik, T., Karall, D., Martinelli, D., Molema, F., Sass, J. O., Scholl-Bürgi, S., Tal, G., Williams, M., Huemer, M., & Baumgartner, M. R. (2021). Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. Journal of inherited metabolic disease, 44(3), 566-592. https://doi.org/10.1002/jimd.12370
Forny, Patrick, et al. "Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision." Journal of inherited metabolic disease vol. 44,3 (2021): 566-592. doi: https://doi.org/10.1002/jimd.12370
Forny P, Hörster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, Dixon M, Grünert SC, Grunewald S, Haliloglu G, Hochuli M, Honzik T, Karall D, Martinelli D, Molema F, Sass JO, Scholl-Bürgi S, Tal G, Williams M, Huemer M, Baumgartner MR. Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. J Inherit Metab Dis. 2021 May;44(3):566-592. doi: 10.1002/jimd.12370. Epub 2021 Mar 09. PMID: 33595124; PMCID: PMC8252715.
Copy Download .nbib Format: NLM
Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias-A multicenter experience.

Pacing and clinical electrophysiology : PACE

Attanasio P, Huemer M, Kaehler N, Keller T, Schreiber T, Niehues R, Katsani-Potempa D, Klein RM, Landmesser U, Deisenhofer I, Tutdibi O, Bourier F.
PMID: 33665850
Pacing Clin Electrophysiol. 2021 May;44(5):807-813. doi: 10.1111/pace.14205. Epub 2021 Mar 15.

INTRODUCTION: Despite the development of non-fluoroscopic catheter visualization options, fluoroscopy is still used in most ablation procedures. The aim of this multicenter study was to evaluate the safety and efficacy of a new ultra-low dose radiation protocol for EP...

Cite
Attanasio P, Huemer M, Kaehler N, et al. Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias-A multicenter experience. Pacing Clin Electrophysiol. 2021;44(5):807-813doi: 10.1111/pace.14205.
Attanasio, P., Huemer, M., Kaehler, N., Keller, T., Schreiber, T., Niehues, R., Katsani-Potempa, D., Klein, R. M., Landmesser, U., Deisenhofer, I., Tutdibi, O., & Bourier, F. (2021). Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias-A multicenter experience. Pacing and clinical electrophysiology : PACE, 44(5), 807-813. https://doi.org/10.1111/pace.14205
Attanasio, Philipp, et al. "Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias-A multicenter experience." Pacing and clinical electrophysiology : PACE vol. 44,5 (2021): 807-813. doi: https://doi.org/10.1111/pace.14205
Attanasio P, Huemer M, Kaehler N, Keller T, Schreiber T, Niehues R, Katsani-Potempa D, Klein RM, Landmesser U, Deisenhofer I, Tutdibi O, Bourier F. Safe procedures despite ultra low radiation doses during catheter ablations of atrial and ventricular arrhythmias-A multicenter experience. Pacing Clin Electrophysiol. 2021 May;44(5):807-813. doi: 10.1111/pace.14205. Epub 2021 Mar 15. PMID: 33665850.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 91 entries